OSCA: A System For Efficient Construction Of Adenovirus Vectors

Inventor(s):

    SUMMARY

    • Adenoviruses (Ad) are a non-enveloped linear double-stranded DNA viruses with over 50 serotypes identified in humans.  They have received significant attention as an in vitro and in vivo gene delivery vehicle due to their well-defined virology/biology, viral genetic stability, high gene transduction efficiency, and ability to be produced in a large scale.  Ad-vectors are used as delivery vehicles to express transgenes, to express siRNAs for gene silencing, and/or CRISPR/Cas and designer nucleases systems for genome editing.
    • Even though Ad-vectors offer many advantages as compared with other viral vectors used for gene delivery and they have been widely employed, the initial generation of a given Ad-vector is a technically challenging and time-consuming process, making development of a simpler and more efficient construction process desirable.
    • Inventors have evaluated a technique to simplify the Ad-vector making process by developing a one-step construction of adenovirus (OSCA) system using Gibson DNA Assembly (GDA) technology. The developed OSCA system uses the Ad recipient vectors containing the bacterial suicide gene ccdB flanked with two 20-bp unique sequences; MOS1 and MOS2, which serve as universal sites for GDA reactions at the Ad genome E1 region.
    • Proof-of-principle experiments indicated that GDA reactions were highly efficient producing >95% positive colonies, and that resultant recombinant Ad plasmids were effectively packaged into adenoviruses within 7 days in 293ptP cells. Ad-vector mediated expression of mouse BMP9 was also shown to efficiently induce osteogenic differentiation of mesenchymal stem cells. 

     

    FIGURE


    OSCA System using Gibson DNA Assembly Technology

     

    ADVANTAGES

    ADVANTAGES

    • Developed OSCA system streamlines/simplifies the Ad-vector making process 
    • Technology facilitates Ad-based applications for use in basic, translational, and clinical research 

     

    APPLICATIONS

    • Gene therapy
    • Vaccine development

    TECH DETAILS

    Published
    1/4/2022

    Reference ID
    21-T-143

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager of Market Intelligence, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.

    Accept